A Comprehensive Evaluation of CAR-T Cell Gene Therapy, Tracing its Revolutionary Clinical Breakthroughs and Advancements Towards Next-Generation Engineering

BACKGROUND: CAR-T cell gene therapy has advanced from an experimental concept to a standard curative treatment for selected hematologic malignancies. Substantial clinical evidence has established CAR-T therapy as a cornerstone for relapsed/refractory B-cell malignancies and multiple myeloma, demonstrating durable, long-term remissions. In 2025, the U.S. Food and Drug Administration (FDA) eliminated the Risk Evaluation and Mitigation Strategy (REMS) requirement, reflecting improved clinical management of Cytokine Release Syndrome (CRS) and Immune Effector Cell-Associated Neurotoxicity Syndrome (ICANS). Yet, the widespread adoption of these therapies has unveiled a new landscape of long-term and next-generation challenges. METHODS: This review critically analyzes CAR-T therapy's clinical trajectory and the bioengineering strategies redefining its safety, scalability, and translational potential. RESULTS: A major hurdle is therapeutic resistance driven by antigen escape, notably through alternative splicing and lineage switching. The emergence of long-term safety signals, specifically secondary T-cell malignancies, has necessitated rigorous surveillance, exemplified by the European Medicines Agency's (EMA) mandate for lifelong patient monitoring. The therapeutic landscape is further complicated by histopathological and immunological barriers limiting the expansion and persistence of engineered cells. These include deficient T-cell trafficking, an immunosuppressive tumor microenvironment (TME), and antigen heterogeneity, which have historically constrained efficacy in solid tumors. To address these hurdles, the field is leveraging CRISPR-enhanced allogeneic platforms, cytokine-secreting armored CARs (TRUCKs), and logic-gated systems showing early clinical promise. CONCLUSION: Building on these developments, we hypothesize that CAR-T therapy is undergoing a paradigm shift from single-target cytotoxicity toward a multi-functional, programmable framework capable of overcoming resistance, enhancing safety, and enabling effective penetration of solid tumors.